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Solid dispersion of calcitriol with lipophilic surfactants and triglycerides was developed by
melt-mixing method to modify the release and enhance stability of the drug. The solid dis-
persions were characterized by differential scanning calorimetry (DSC), hot stage polarized
optical microscopy (HSPM), infrared spectroscopy (FTIR) and stability studies. The solid
dispersion significantly enhanced the stability of calcitriol, which could be attributed to the
high antioxidant activity of the solid lipid dispersion. The rapid dissolution rate from the
solid dispersion was attributed to the amorphous or solid solution state of drug with
improved specific surface area and wettability than the drug crystals. Therefore, solid
dispersion of calcitriolwith D-a-tocopheryl polyethylene glycol 1000 succinate (TPGS) offers a
good approach to modify the release and enhance stability of calcitriol. The influence of
lipophilic solid dispersion on drug bioavailability needs further investigation.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction showed remarkable effect on cancers such as prostatic car-Calcitriol is the biologically active form of cholecalciferol in
the intestine, proved to be 4e13 fold active as cholecalciferol
in stimulating intestinal calcium transport [1] and play an
important role in the regulation of calcium metabolism [2].
Moreover, calcitriol has been proved effective in treatment of
osteoporosis, glucocorticoid-induced osteoporosis, secondary
hyperparathyroidism and psoriasis [2e5]. In addition, itical Sciences, Sun Yat-Sen
u).
g Pharmaceutical Univer
sevier
ang Pharmaceutical Univcinoma, osteosarcoma, leukemia, etc [6e8].
However, even with the demonstrated excellent efficacy,
calcitriol plays a limited pharmaceutical role mainly because
of its exceptionally low aqueous solubility and extreme sus-
ceptibility to light, heat and oxygen [9], which induced a big
challenge for developing calcitriol into a stable and thera-
peutically effective dosage form. The conventional calcitriol
oral products, Rocaltrol soft capsule and Rocaltrol oralUniversity, University Town, Guangzhou 510006, China. Tel.: þ86
sity
ersity. Production and hosting by Elsevier B.V. All rights reserved.
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industrial applicability and the liquid formulations showed
severe inherent stability issue.
The current trend in calcitriol research is concentrated on
the development of potential delivery system to increase its
stability against oxygen. Libertyville [10] designed low oxygen
content compositions of calcitriol, i.e. a unit dose system
comprising 1a,25-dihydroxycholecalciferol in a sealed vessel.
Paul [11] and Paulhaguet [12] added antioxidants such as
tocopherol and BHT respectively to enhance the stability of
calcitriol. By far, there were few reports on solid formulation
of calcitriol.
Solid dispersion is one of the most effective approaches to
improve dissolution rate and hence bioavailability of poorly
water-soluble drugs at solid state [13]. Out of the many poly-
mers, biocompatible lipid materials are widely used as car-
riers for solid dispersion systems because of their ability to
solubilize hydrophobic drugmolecules, as well as the ability to
stabilize solid dispersion by drugecarrier interactions and/or
antiplasticizing effects of the carrier. It is known solid dis-
persions are thermodynamically unstable with the high en-
ergy input during preparation [14]. The representative lipid
materials include surface-active carriers like TPGS (D-a-toco-
pheryl polyethylene glycol 1000 succinate), and Janssens [14]
observed the improved dissolution of solid dispersion made
of itraconazole and TPGS. In addition, Yoo [15] reported
excellent miscibility and stability of TPGS and polymers as
carriers of solid dispersions.
Recently, melting method has gained popularity for pre-
paring solid dispersion due to many advantages, such as free
of solvents, simple procedure and uniform product quality
[16]. For this method, the melting temperature must be high
enough to ensure that the drug is completely melted and
transformed to amorphous state. But at high temperature,
both drug and polymer carrier faces the risk of thermal
degradation, especially for heat sensitive drugs [17]. There-
fore, lowering the process temperature of melting method is a
big challenge for pharmaceutical scientists.
It was found that the melting point of solid lipid would
decrease upon adding of medium chain triglycerides (MCT).
Jenning reported that the melting point of glyceryl behenate
(85 C) was depressed in a concentration dependent manner
with the addition of Miglyol to carrier [18]. As excellent and
stable solvents for water-insoluble drugs, MCT are compatible
with other cosolvents, lipids and surfactants [19] and there-
fore, were used in the commercial product of calcitriol i.e.
Rocaltrol.
In addition, silicon dioxide can be used as liquisolid car-
riers to overcome the stickiness and tackiness problems of
lipid carriers for further investigation such as tableting [20,21].
The abilities of solid dispersion to incorporate drug for
immediate release and enhancing drug bioavailability make it
an interesting drug delivery system for oral administration.
However, few literature have assessed the application of solid
dispersion for delivery of calcitriol.
Therefore, the objective of this research was to develop
solid dispersion by using MCT and TPGS as lipid carriers and
SiO2 as solidifier, in order to improve the solubility of calcitriol
in aqueous media and enhance the stability of calcitriol.
Furthermore, a complete characterization of the soliddispersion properties and of the drug/carrier interactions was
conducted by using differential scanning calorimetry (DSC),
hot stage polarized optical microscopy (HSPM), Fourier
transform infrared spectroscopy (FTIR). Also, the stability and
dissolution behavior of calcitriol in solid dispersion were
evaluated.2. Materials and methods
2.1. Materials
Calcitriol was supplied by Guangzhou Eastbang Pharm. Sci. &
Tech. Co., Ltd (Guangdong, China). D-a-Tocopheryl polyethylene
glycol 1000 succinate (TPGS) was obtained from Aladdin Re-
agent Factory (Shanghai, China). Medium chain triglycerides
(MCT) were supplied by Xiya Reagent Factory (Sichuan, China).
Colloidal silicon dioxide (SiO2) was obtained from Huzhou
Zhanwang Pharmaceutical Co, Ltd (Zhejiang, China). All other
materials used were of analytical or HPLC grade.
2.2. Preparation of solid dispersion
Solid dispersion was prepared by melt-mixing method. Firstly,
calcitriol was dissolved in MCT under ultrasonication, then
TPGS premelted at 60 C was mixed with calcitrioleMCT solu-
tionwith vortexing until a homogeneousmixturewas obtained.
The mixture was then dispersed into SiO2 and cooled to 5 C
immediately to form solid dispersions containing 0.0001% of
drug, 29.6% of MCT, 29.6% of TPGS, and 40.8% of SiO2.
2.3. Preparation of physical mixture
Physical mixture with the same composition of solid disper-
sion was also prepared. TPGS was first melted at 60 C, and
vortex-mixed with MCT to form a homogeneous mixture. The
melt was then dispersed into SiO2 and cooled to 5 C imme-
diately. The obtained particles were then blended with crystal
calcitriol uniformly.
2.4. Stability study
The dispersion samples were placed in sealing containers and
stored at 5 C (refrigerator), or in controlled temperature
cabinets at 25 C (60% RH), 30 C (65% RH) and 40 C (75% RH).
The physicochemical properties of these dispersions were
evaluated after 0, 5, 10, 30, 60, 90 days.
2.5. Thermal analysis
Thermal behavior of the samples was examined by differen-
tial scanning calorimetry (DSC 200 F3 Maja, NETZSCH group,
Germany). Samples of 1e10 mg were placed in open
aluminum pans and heated at 10 C/min to 130 C under a
nitrogen flow rate of 30 ml/min.
2.6. Hot stage polarized optical microscopy (HSPM)
The solid dispersion samples stored over 3 months (25 C,
60% RH) after preparation were examined in a hot-stage
microscope (Polarizing Microscope Mshot MP41, combined
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 3 9e4 7 41with a heating unit, the precisionworking table KER3100-08S,
China). The samples were heated at 10 C/min until the lipids
(MCT and TPGS) melted (27e42 C) and the temperature was
then kept constant for 1 min for photographing. Since the
melting temperature of crystalline calcitriol is 115 C and the
lipids melted at markedly lower temperatures, crystalline
calcitriol could be seen if calcitriol and the lipid had not
formed a solid dispersion. For comparison, HSPM photo-
graphs of the particles containing only lipophilic excipients
were taken as well.
2.7. Fourier transform infrared spectroscopy (FTIR)
Molecular interaction between drug and excipients was
determined using Fourier transform infrared spectrometer
equipped with a KBr beam splitter (TEN-SOR37, Bruker,
Germany). Samples were prepared according to the KBr
technique and examined in the transmission mode, with the
scan range of 400e4000 cm1, 64 scans per spectrum and a
resolution of 4 cm1. Software Bruker OPUS 6.5 was used for
data analysis.
2.8. Crystallinity of the lipid mixtures
The miscibility of the mixtures composed of excipient and
drug/excipient was semi-quantitatively estimated by assess-
ing the presence of crystallinematerial. As themiscibility level
is inversely proportional to the crystallinity level, mixtures
exhibitinghighcrystallinity are consideredphysically instable.
The crystallinity index (CI) can be computed as the following:
CI% ¼ DHlipid dispersion
DHbulk material
 100
where DHlipid dispersion and DHbulk material are the melting
enthalpy (J/g) of lipid dispersion and bulk lipid, respectively.
2.9. Solubility parameter
Partial solubility parameter (d) defined by Hildebrand, was
calculated using group contribution method [22,23] as the
following:
dd ¼
X
Fdi=
X
V
dp ¼
X
F2pi
1=2
=
X
V
dh ¼
X
Ehi=
X
V
1=2
d2t ¼ d2d þ d2p þ d2h
Dd ¼
h
ðdd;e  dd;dÞ2 þ

dp;e  dp;d
2 þ ðdh;e  dh;dÞ2
i1=2
where Fdi, Fpi and Ehi represented the group contributions to
the dispersion, the polar component of the molar attraction
constant and the hydrogen bonding energy, respectively.
Hansen subdivided the total Hildebrand value dt into three
fractions: dispersive interactions (dd), polar interactions (dp)
and hydrogen bonding (dh). Dd represented the total solubilityparameter, the differential value of the drug/excipient solu-
bility parameter and V represented molecular volume. The
contribution value of groups had been summarized by Barton
[41]. The difference of solubility parameters between drug and
each excipient (Dd) was determined to evaluate themiscibility
between the materials.2.10. In vitro dissolution studies
The dissolution test was performed using the small glass
method [24] at a stirring rate of 100 rpm and at 37  0.5 C in a
dissolutor ZRS-8 G (Tianda Tianfa Technology Co., Ltd.,
China). Samples equivalent to 0.1 mg of calcitriol were added
to the dissolution medium (100 ml of distilled water with 0.5 g
of sodium dodecyl sulfate). At appropriate time intervals,
2.0 ml of aliquots were withdrawn and replaced with an equal
volume of fresh dissolution medium. Aliquots were filtered
through a millipore filter (0.22 mm) and detected for calcitriol
content by high-performance liquid chromatography (HPLC)
in sextuplicate.2.11. HPLC analysis
Concentration of calcitriol was determined using a HPLC
system (Dionex Corporation, Sunnyvale, CA) which consisted
of a Dionex P680A LPG-4 pump, a Dionex UVD-170U UV de-
tector, a Dionex AST-100 automated sample injector, and a
computer installed with software Chromeleon version 6.80.
Separation was achieved by using an Acclaim HP-C18 col-
umn (5 mm, 120 A, 4.6  150 mm) with the mobile phase con-
sisting of acetonitrile and water at a volume ratio of 55:45 for
0e18 min and 95:5 for 19e30 min. The flow rate of the mobile
phase was 1 ml/min and the injection volume was 20 ml. All
chromatographic separationswere performed at 25 C and the
wavelength of detection was set at 265 nm.
For HPLC assay, 100 mg of solid dispersion (containing
0.001 mg of calcitriol) was dissolved in with methanol at a
ratio of 1:1 (w/v). All analyses were performed in triplicate at
ambient temperature.2.12. Statistics
All data were presented as mean  standard deviation (S.D.).
Significance of difference was evaluated using Student’s t-test
and one way ANOVA at the probability level of 0.05.3. Results and discussion
3.1. Solubility parameters
Similarity in the solubility parameters (d) of the drug and ex-
cipients was used initially to screen the excipients to be used
as carriers in the solid dispersions. Compounds with similar
values of solubility parameters are likely to be miscible [26]. If
the drug and the carrier are immiscible, their dispersion can
be problematic with irregular crystallization, uniformity issue,
and possibly less or no improvement in drug dissolution.
Greenhalgh [25] demonstrated that compounds with a
Table 1 e Calculated partial solubility parameters of drug
and excipients.
Sample dd (MPa
1/2) dp (MPa
1/2) dh (MPa
1/2)
Calcitriol 19.10 2.76 9.71
MCT 17.54 2.66 4.20
TPGS 18.02 2.25 5.94
Table 2eMelting enthalpy and crystallization behavior of
drug-loaded lipid dispersions.
MCT/TPGS (w/w) DH (J/g) Melting point (C) CI %
0:1 84.51 36.7 100.0
1:2 45.11 35.7 53.4
1:1 31.30 33.7 37.0
3:2 25.51 33.3 30.2
3:1 14.31 31.3 16.9
6:1 6.32 27.9 7.5
9:1 2.79 27.4 3.3
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a Dd > 10 MPa1/2 are likely to be immiscible.
Based on the values of calculated partial solubility param-
eters summarized in Table 1, Dd (MCT/TPGS) ¼ 1.85 MPa1/2, Dd
(calcitriol/MCT)¼5.73MPa1/2,Dd (calcitriol/TPGS)¼3.96MPa1/2,
which implied high possibilities of homogenous dispersion of
calcitriol in the lipid carriers composed of MCT and TPGS.3.2. Physicochemical characteristics of lipid mixtures
DSC is frequently used to evaluate the physicochemical sta-
bility by measuring the heat loss or gain within a sample as a
function of the temperature. It can monitor the melting and
crystallization behavior of crystalline materials such as lipid
nanoparticles [27].
Fig. 1 givesanoverviewof themeltingprocess of drug-loaded
lipidmixturespreparedwithMCTandTPGSatdifferent ratiosby
melt-mixing method. For the upper curve, the melting process
takes place with melting point at 36.7 C (peak maximum). The
extrapolated onset of themelting process occurs at 26.6 C. The
difference between onset and maximum can be taken as a
measure for the width of the peak and is in this case 10.1 K. At
75%MCT load themelting point is depressed by almost 10.4 K to
31.3 C. The temperature of the maximum for these lipid mix-
tures with the highest MCT load decreased at 27.4 C. It showed
that themelting temperaturewasdecreasedwith the increaseof
MCTcontent inthe lipidmixtures.Thismeltingpointdepression
can be described by the GibbseThomson equation [27].
Generally, the increase of melting enthalpy and crystal-
linity index (CI %) during storage indicates the instability of
the drug-loaded lipid mixtures. Lipids with high energy tend
to form ordered crystal lattice, resulting in drug expulsion [18].
High storage temperature and exposure to light could-16 -4 8 20 32 44 56 68 80
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Fig. 1 e DSC curves of drug-loaded lipid mixtures (0.001% of
calcitriol) with different ratios of MCT and TPGS.stimulate the increasing of CI % [28]. Themelting enthalpy and
CI % of the drug-loaded TPGS/MCT lipid dispersions (Table 2)
showed that the crystallinity was reducedwith the addition of
MCT. As a result, higher concentration of MCT in lipids
accompanied by lower crystallinity led to better physical sta-
bility of solid dispersions. After 90 days of storage, themelting
enthalpy DH of the mixed lipids did not show any marked
change (data not shown) which indicated the storing stability
of the preparations.
It was observed that the predominant physical state in the
lipid carriers was less ordered crystals or even amorphous
phase. Due to their low melting point and complex composi-
tion, the recrystallization after production by melting method
is considerably retarded. Similar observations were reported
by Han [27] that adding liquid lipid triglyceride into solid lipid
could obtain a less ordered matrix.3.3. Thermal analysis
DSC can provide an insight into the melting behavior of
crystalline material, so in this case it is a useful mean to un-
derstand the drug and lipid interactions and the melting be-
haviors of TPGS, MCT and calcitriol in the solid dispersions
[18]. The DSC thermograms of physical mixture and solid
dispersion of calcitriol showed a similar broad endothermic
peak ranging from 34 to 37 C, indicating the melting point of
lipid-SiO2 carrier (Fig. 2). While the diagram of pure calcitriol150100050
H
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Fig. 2 e DSC thermograms of different samples, (A):
calcitriol solid dispersions; (B): calcitriol physical mixtures;
and (C): pure calcitriol.
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and two peaks at 60 C and 82 C representing another two
forms of calcitriol crystal [29]. However, the absence of
endothermic peak of calcitriol in physical mixture, which was
different from most observations [30,31], might be attributed
to the effect of carriers inhibiting the crystallization of drug or
the low sensitivity of DSC to crystal detection.
3.4. Solid state of drug in dispersion
Hot stage polarized optical microscopy (HSPM) is often
combined with DSC to characterize the solid state form of
drug in solid dispersions [17,32] by providing information
about the differences in crystallinity between the samples.
However, the results of HSPM should be interpreted with
care, as only a few particles from each sample were exam-
ined. HSPM micrographs (Fig. 3a and b) illustrated that pure
calcitriol was a crystalline compound completely melting at
115, while lipids showed crystals of irregular shapes and
sizes melting at 40 C. Solid dispersion was quite distinct
from the physical mixture as the drug and excipients seemed
to have lost their original crystallographic habits [33]. More
crystals were observed in the physical mixtures than in theFig. 3 e HSPMmicrographs of phase transition during heating pr
lipids physical mixtures; (d) calcitriol lipid dispersions (without
calcitriol solid dispersions.corresponding solid dispersions. By heating up to 40 C, the
crystals in physical mixture reduced as the lipids melting
and flowing, and disappeared at 115 C (Fig. 3c and e).
Differently, the crystals in solid dispersions melted at 40 C
(Fig. 3d and f). This might be attributed to the effect of car-
riers that inhibited the crystallization of drugs [34], resulting
in an amorphous state or a solid solution of calcitriol in solid
dispersions.
3.5. FTIR
To elucidate further physicochemical properties, infrared
absorption spectroscopy was carried out. The infrared spec-
trum of pure calcitriol showed a broad absorption band at
3288 cm1, assigned to the stretching vibration of hydroxyl
group, and a sharp band at 2935 cm1 and 2870 cm1, assigned
to the asymmetric and symmetric stretching vibrations of
CeH bond, respectively (Fig. 4). The 1640 cm1 and 1470 cm1
bands are due to the stretching vibration of C]C and CeO
bonds respectively, which are corresponding to the observa-
tions by Chen [35]. The spectrum of physical mixture showed
the characteristic peak of calcitriol at 3288 cm1, which was
not observed in the spectrum of solid dispersion. Theocesses: (a) pure calcitriol; (b) lipid carriers; (c) calcitriol and
SiO2); (e) calcitriol and lipid-SiO2 physical mixtures; and (f)
4000 3500 3000 2500 2000 1500 1000 500
Wavenumber (cm-1)
(C)
T 
(%
) (B)
(A)
Fig. 4 e FTIR spectra of calcitriol solid dispersion (A),
calcitriol physical mixture (B) and calcitriol (C).
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compared to pure calcitriol and physical mixture, and this
shift may be attributed to the melting process itself. Other
minor changes in the spectra can be attributed to the possible
drug crystal modifications [36,37]. Therefore, it could beFig. 5 e Percentage of calcitriol in solid dispersions with
different drug loading at 0 day (A), and after 30 days of
storage at 25 C (B).presumed that an interaction might exist between the func-
tional groups of calcitriol and lipophilic excipients in the solid
dispersion at the molecular level. The most probable associ-
ation is expected to be between the hydroxyl group of calci-
triol and the hydrogen group of lipophilic excipients. Overall,
the results of spectrum analysis indicated that calcitriol likely
existed as a partial solid solution in the solid lipid dispersions
and its crystallinity was weakened through the molecular
interactions with the excipients.
3.6. Stability study
The stability experimentwas carried out in sealed containers to
investigate the formulation parameters, including drug loading,
temperature, and ratio between MCT and TPGS, affecting the
stability of calcitriol-loaded solid dispersions (CAL-SD).
3.6.1. The effects of drug loading on stability
Due to the high solubility of calcitriol in MCT, four solid dis-
persions with different drug loading from 0.0001% to 0.1%
calcitriol (Fig. 5) were prepared to determine the most stable
formulation. No significant difference in drug content was
observed between the formulations even with the highest and
lowest drug loading after 30 days of storage at 25 C (Fig. 5B).
This is different from most studies that drug loading was
related to thestabilityof soliddispersion [28]. Thismightbedue
to the excellent similarity in the present dispersion model.
Briefly, during the production by melting-mix technique, drugA
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ately; therefore, even at high drug loading calcitriol was
dispersed evenly in lipid carriers. The common re-partition of
drug into the lipidphase leading to the ‘drugenrich core’model
for re-crystallization [38,39] was hardly to occur.A
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Fig. 8 e (A) Dissolution of calcitriol in 0.5% SDS medium at
37 C, 100 rpm (n [ 6); (B) Dissolution of calcitriol solid
dispersion stored at 25 C RH 60% for three months.3.6.2. The effects of temperature on the stability
It is known that the increase of temperature can increase the
reaction rate through themechanismofArrhenius equation [28]
to cause the stabilityproblem.Thechangeofcalcitriol content in
solid dispersion and pure drug after storage at 40 C and 25 C
revealed that temperature had a strong effect on the stability of
bothpure drug and solid dispersion in sealed container (Fig. 6A).
But obviously, the solid dispersion exhibited improved stability
of calcitriol at elevated temperature.
As the storage temperature was lowered to 30 C, calcitriol
in solid dispersion showed a long-term (3 months) stability
with drug content higher than 95% at both 25 C, RH 60% and
30 C, RH 65% (Fig. 7).
3.6.3. The effects of TPGS concentration on the stability
The change of calcitriol content in solid dispersions prepared
from different concentration of TPGS during storage at 25 C
was illustrated in Fig. 6B. By comparing the difference in the
mean of drug content using one way ANOVA, it was found that
the stability of calcitriol in solid dispersions with different
concentration of TPGS was significantly different from each
other ( p < 0.05), and the drug stability was strongly dependent
on the concentration of TPGS.When the concentration of TPGS
reached 50% (related to lipids), calcitriol in solid dispersion
showed the best stability. This stability enhancement could be
attributed to that TPGS, a water-soluble derivative of natural
vitamin E, can act as an antioxidant and stabilizer. As a result,
calcitriol molecules could be protected from oxygenmolecules.
This was also reported by Cleland and Carlos [40], where the
stability of active vitamin D compound was improved after
incorporation of antioxidants during the production process.
3.7. In vitro dissolution studies
The effect of lipids on the dissolution of calcitriol was inves-
tigated. As shown in Fig. 8A, the amount of calcitriol dissolved
from 0.1% CAL-SD rapidly and markedly exceeded the disso-
lution of calcitriol from pure drug and drug physical mixture
(only 14%). It was presumed that the mixed lipid melted and
dissolved in the dissolutionmediumof 37 C quickly and TPGS
acted as an emulsifier for hydrophobic calcitriol.
The effect of storage conditions on the dissolution
behavior of the solid dispersions was also evaluated. The
representative dissolution profiles of 0.0001% CAL-SD stored
at 25 C 60% RH for up to 3 months (Fig. 8B) showed no sig-
nificant change. Similar observation was obtained for disso-
lution of calcitriol lipid dispersions at stored 30 C 65% RH for 3
months (data not shown). It indicated that the calcitriol solid
dispersion remained stable when stored at 25 C and 30 C.4. Conclusion
Solid dispersions of calcitriol were prepared by melt-mixing
method using MCT, TPGS and SiO2 as carriers. With the
reduced crystallinity, the dissolution rate of hydrophobic drug
from solid dispersions was increased, and the stability of the
preparation was improved by selecting suitable carriers and
proper storage conditions. Combining MCT and TPGS in the
molten state to form solid dispersion uniform lipid carriers
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 3 9e4 746offers a promising approach to decrease the melting temper-
ature of drug and improve the dissolution and stability.
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